GRAPHENE CONJUGATED USNIC ACID NANO-FORMULATION FOR THE TREATMENT OF TOPICAL FUNGAL INFECTION
Objective: The study aims to investigate the antifungal response of the dug usnic acid with the carrier graphene.
Methods: Nano-precipitation method by sonication was adopted to formulate the conjugate. SEM test was performed to check the shape and average size of the conjugate. FTIR test was performed for the chemical interaction between the drug and the carrier. Ointment was prepared by the fusion method and the viscosity test was performed by Brookfield viscometer. Spreadability test was performed by slide method. Animal activity was performed to confirm the antifungal effect of the formulated nano-conjugate. Statistical analysis was done by Anova.
Results: SEM study shows that the conjugate is in the nano range and possess a spherical shape. FTIR study shows no interaction between the drug and the carrier. The result of in vitro drug release study shows that the conjugate posses a higher drug release rate as compared to the drug alone. Topical drug administration is more suitable for the treatment of the fungal infection, so the nano-conjugate was incorporated into the ointment by geometric mixing. The viscosity and the spreadability test were performed on the different formulations of the ointment and the suitable one was selected for the topical administration. Anti-fungal study had been performed on the Wistar albino rats for 6 d. Skin culture of rats was performed for the formation of the fungal colonies. Statistical analysis by Anova gives p<0.001. It was found that the normal form of usnic acid, graphene and the nano form both possess anti-fungal activity as 3/6 and 2/6 experimental animals are cured by normal formulation and nano-formulation.
Conclusion: The present anti-fungal study revealed that the nano-form of the conjugate possess higher anti-fungal activity than the normal formulation of usnic acid with graphene.
2. Vyas, Khar. “Targeted and controlled drug delivery” 1st edition. CBS Publishers and Distributors Pvt. Ltd. 2013. p. 331-86.
3. Pandian Sundara M, Karthikeyini Chitra S, Nagarjan M. Fabrication, characterization and pharmacological activity of usnic acid loaded nanoparticles. Int J Pharm Sci Res 2017;8:4758-66.
4. Krzeminska Guzow. Antibacterial activity of lichen secondary metabolic usnic acid is primary caused by inhibition of RNA and DNA. FEMS Microbiol Lett 2014;353:57-62.
5. Pandey. Synthesis and characterization of graphene-usnic acid conjugate microspheres and its antibacterial activity against staphylococcus aureus. Int J Pharm Sci Res 2019;10:939-46.
6. Gupta SK. Introduction to pharmaceutics II” fourth edition. CBS Publishers and Distributors Pvt. Ltd; 2011. p. 184-215.
7. Nayak SH, Nakhat PD, Yeole PG. Development and evaluation of cosmeceutical hair styling gels of ketoconazole. Indian J Pharm Sci 2005;52:231-33.
8. Jain S, Padsalg BD, Patel AK, Moale V. Formulation development and evaluation of fluconazole gel in various polymer base. Asian J Pharm 2007;1:63-8.
9. Pershing LK, Corlett LJ, Jorgensen C. In vivo pharmacokinet Bics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum Antimicrob. Agents Chemother 1994;38:90–5.
10. Queiroz MBR, Marcelino NB, Ribeiro MV, Espindola LS, Cunha F, Silva MV. Development of gel with Matricaria recutita L. extract for topical application and evaluation of physical-chemical stability and toxicity. Lat Am J Pharm 2009;28:574-9.
11. Bhattacharya Sankha, Prajapati G Bhupendra. Formulation and optimization of celecoxib nanoemulgel. Asian J Pharm Clin Res 2018;11:353-65.
12. S Princely, MD Dhanaraju. Design, formulation and characterization of liposomal encapsulated gel for transdermal delivery of fluconazole. Asian J Pharm Clin Res 2018;11:417-24.
13. Nihal Badduri, Gupta Vishal N, Gowda DV, M Manohar. Formulation and development of anti acne formulation of Spirulina Extract. Int J Appl Pharm 2018;10:229-33.
This work is licensed under a Creative Commons Attribution 4.0 International License.